Editas gets Australian clearance to start Strive trial of EDIT-401, reports Q3 2026 resultsNov 9Quarterly updateEditas Medicine, Inc.
Editas Medicine receives approval to initiate Phase 1/2 trial of EDIT-401Oct 8Regulatory decisionEditas Medicine, Inc.
Editas reports Q2 2026 results, plans Australia CTN filing for EDIT-401Aug 5Quarterly updateEditas Medicine, Inc.